吉非替尼治疗晚期非小细胞肺癌的安全性分析  

Gefitinib in Treatment of Advanced NSCLC of Security Analysis

作　　者：李长颖[1] 王波[1] 

机构地区：[1]大连大化集团有限责任公司医院,辽宁大连116031

出　　处：《医学与哲学（B）》2012年第6期34-35,共2页Medicine & Philosophy(B)

摘　　要：分析吉非替尼治疗晚期非小细胞肺癌的安全性。对92例晚期非小细胞肺癌患者给予吉非替尼250mg/d口服治疗,应用至病情进展或不良反应不能耐受停药,评价其不良反应。结果92例患者中皮疹发生率为67.39%(62人),腹泻发生率为25%(23人),其中1例发生间质性肺炎,1例出现急性肾功能不全,4例出现转氨酶增高。吉非替尼对晚期NSCLC的疗效好,但可以出现皮疹,腹泻,肝肾损害,间质性肺炎等不良反应。Analysis of Gefitinib in treatment of advanced non-small cell lung cancer （NSCLC） safety. In 92 cases of advanced NSCLC patients given Gefitinib 250rag daily treatment were followed up endpoint is either the disease progress or drug withdrawal because of adverse reaction. In 92 patients the rash occurs at a rate of 67.39% （62）, diarrhea occurred at a rate of 25 % （23）, including 1 cases of interstitial pneumonia, 1 cases of acute renal dysfunction,4 cases appeared transaminase. Gefitinib for advanced NSCLC curative effect is good, but can be a skin rash, diarrhea, liver and kidney damage, interstitial pneumonia and other adverse reactions.

关 键 词：吉非替尼 非小细胞肺癌 安全性 

分 类 号：R734.2[医药卫生—肿瘤]